Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus
Status:
NOT_YET_RECRUITING
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
To assess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China.